Skip to content Skip to footer
Viewpoints_Efrat Kaduri

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots:  Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells  Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors  While highlighting the intellectual…

Read more